{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-292080","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.411214+00:00","generated_at":"2026-06-07T14:59:32.963987+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TScan Phase 1 TCR-T data: 6/6 patients achieve complete donor chimerism and MRD negativity; 0/4 controls","bullets":["All 6 evaluable patients treated with TSC-100 or TSC-101 achieved complete donor chimerism and MRD negativity; none of 4 control-arm patients achieved these endpoints.","One AML patient MRD-positive post-HCT converted to MRD-negative after TSC-101 treatment.","Control arm: one TP53-mutated MDS patient relapsed at ~6 months; two others had worsening chimerism requiring clinical intervention.","Dose escalation reached third and final level with no dose-limiting toxicities; recommended Phase 2 dose expected from this level.","Company hosting virtual KOL event Dec 11 to discuss data; 10 clinical sites active with expansion cohorts planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-292080","json":"https://secwatch.observer/filing/0001193125-23-292080.json","markdown":"https://secwatch.observer/filing/0001193125-23-292080.md","text":"https://secwatch.observer/filing/0001193125-23-292080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523292080/0001193125-23-292080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523292080/d840458d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:59:32.963987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}